Prevention of Neointimal Hyperplasia With Systemic Injection of a Targeted Drug-eluting Peptide Amphiphile

Abstract

The aim of this study is to evaluate a novel systemically delivered targeted therapy that will prevent restenosis following all cardiovascular interventions. To accomplish this aim, our goal is to determine if a peripheral intravenous injection of a nitric oxide (NO)-releasing self-assembled peptide amphiphile (PA) targeted to a unique collagen-binding sequence (SNO-C-PA) will bind to the site of vascular intervention and prevent the development of neointimal hyperplasia following arterial balloon injury. We hypothesize that the SNO-C-PA will bind specifically to the site of vascular injury and prevent neointimal hyperplasia compared to controls.The aim of this study is to evaluate a novel systemically delivered targeted therapy that will prevent restenosis following all cardiovascular interventions. To accomplish this aim, our goal is to determine if a peripheral intravenous injection of a nitric oxide (NO)-releasing self-assembled peptide amphiphile (PA) targeted to a unique collagen-binding sequence (SNO-C-PA) will bind to the site of vascular intervention and prevent the development of neointimal hyperplasia following arterial balloon injury. We hypothesize that the SNO-C-PA will bind specifically to the site of vascular injury and prevent neointimal hyperplasia compared to controls.